Abstract
While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.
